Mardi C. Dier

Mardi C. Dier

Executive Vice President and Chief Financial OfficeratMadrigal Pharmaceuticals· In proxies 2023–2025

Pay in FY2025-30% from the year before · Madrigal Pharmaceuticals stock +88.7% the same year

Mardi C. Dier was paid $6.1M in FY2025 (Dec), down 30%. Madrigal Pharmaceuticals stock rose 88.7% that year.

Pay$100 in the stock at the end of FY23 → $252
Pay is from the Summary Compensation Table of each Madrigal Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Madrigal PharmaceuticalsPublic company · 2 yr
    • Executive Vice President and Chief Financial Officer2024 – Present · 2 yrStock in role +82%
  2. Oric PharmaceuticalsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Healthcare Royalty PartnersPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  4. Synthekine Inc.Public company · 4 yr
    • Director2021 – 2025 · 4 yrNo stock prices for these years
  5. Prelude Therapeutics, Inc.Public company · 5 yr
    • Director2020 – 2025 · 5 yrNo stock prices for these years
  6. Adamas Pharmaceuticals, Inc.Public company · 4 yr
    • Director2017 – 2021 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?